CEFUROXIME AXETIL
Details
- Status
- Prescription
- First Approved
- 2002-02-15
- Routes
- ORAL
- Dosage Forms
- TABLET, FOR SUSPENSION
Companies
CEFUROXIME AXETIL Approval History
What CEFUROXIME AXETIL Treats
9 indicationsCEFUROXIME AXETIL is approved for 9 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Pharyngitis
- Tonsillitis
- Acute Otitis Media
- Maxillary Sinusitis
- Skin Infection
- Urinary Tract Infection
- Gonorrhea
- Lyme Disease
Drugs Similar to CEFUROXIME AXETIL
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
CEFUROXIME AXETIL FDA Label Details
ProIndications & Usage
Cefuroxime axetil tablet is a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria: Pharyngitis/tonsillitis (adults and pediatric patients) Acute bacterial otitis media (pediatric patients) Acute bacterial maxillary sinusitis (adults and pediatric patients) Acute bacterial exacerbations of chronic bronchitis (adults and pediatric patients 13 years and older) Uncomplicated skin and skin-structure infections (adults and pediatric patients 13 years and older) Uncomplicated urinary tract infections (adults and pediatric patients 13 ye...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.